유행성 이하선염 백신(MumpsVax) 시장 보고서(2025년) : 역학, 파이프라인 분석, 시장 인사이트 및 예측

Mumps Vaccine (MumpsVax) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

US $ 4,490 ￦ 6,661,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,629,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,596,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

유행성 이하선염 백신(MumpsVax) 시장 규모는 향후 몇 년 동안 강력한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 백신으로 예방 가능한 질병의 발생률 증가, 성인 백신 접종에 대한 인식 제고, 건강 의식 향상, 예방 접종 프로그램의 확대, 국제적인 건강 이니셔티브의 증가에 기인할 수 있습니다. 예측 기간 동안의 주요 동향으로는 개인 맞춤형 백신 접종 전략, 디지털 건강 통합, 감시 시스템 강화, 성인 백신 접종에 대한 연구 개발, 인공 지능의 통합 등이 있습니다.

전염병의 유행이 증가함에 따라 앞으로 유행성 이하선염 백신(MumpsVax) 시장의 성장이 가속화될 것으로 예상됩니다. 전염병은 바이러스, 박테리아, 곰팡이, 기생충 등 병원성 미생물에 의해 발생하는 질병으로, 개인 간 또는 오염된 환경을 통해 전염될 수 있습니다. 도시화, 기후 변화, 세계화, 인구 통계 및 행동의 변화와 같은 요인들이 병원균의 전염 및 출현을 증가시키는 요인이 되고 있습니다. Mumpsvax는 주로 유행성 이하선염 바이러스에 의해 발생하는 전염병인 유행성 이하선염을 예방하기 위해 사용되며, MMR (홍역, 유행성 이하선염, 풍진) 백신에 포함되는 경우가 많습니다. 예를 들어, 2024년 8월 영국 보건 보안청(UK Health Security Agency)은 홍역 환자 수가 증가했다고 보고했으며, 2023년에는 웨스트 미들랜드 지역이 가장 많은 환자가 발생하여 광범위한 전염병 예방 노력의 일환으로 유행성 이하선염 백신 접종이 증가했습니다. 따라서 전염병의 증가는 유행성 이하선염 백신(MumpsVax) 시장을 촉진합니다.

의료비 지출의 증가는 유행성 이하선염 백신(MumpsVax) 시장의 성장을 촉진할 것으로 예상됩니다. 의료비 지출은 개인 의료, 예방 서비스, 건강 개선을 위한 공중 보건 사업 등 의료 서비스 및 의료 제품에 지출된 총 금액을 의미합니다. 인구 고령화, 만성 질환, 첨단 의료 기술, 서비스에 대한 수요 증가와 같은 요인들이 의료비 지출의 증가에 기여하고 있습니다. 이러한 증가는 예방 접종 프로그램에 대한 자금을 개선하여 백신 접근성을 높이고 예방 접종률을 높임으로써 Mumpsvax에 직접적인 영향을 미칩니다. 예를 들어, 2024년 5월 영국 국가통계청(Office for National Statistics)은 2022년부터 2023년까지 총 의료비 지출이 5.6% 증가했다고 발표하며, 백신 접종에 대한 자금을 강화하고 공중 보건 성과를 개선할 것이라고 밝혔습니다. 따라서 의료비 지출의 증가는 유행성 이하선염 백신(MumpsVax) 시장을 촉진합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 바이오의약품 시장에서의 제품 특성

• 분자 유형
• 투여경로(ROA)
• 작용기전(MOA)
• 안전성과 유효성

제4장 시장 동향과 전략

제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제6장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 유행성 이하선염 백신(MumpsVax) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 유행성 이하선염 백신(MumpsVax) 시장 : 성장률 분석
• 세계의 유행성 이하선염 백신(MumpsVax) 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 유행성 이하선염 백신(MumpsVax) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 유행성 이하선염 백신(MumpsVax) : 전체 시장 규모(TAM)

제7장 세계 시장의 가격 분석과 예측

제8장 시장 세분화

• 세계의 유행성 이하선염 백신(MumpsVax) 시장 : 제품 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 1가
• 조합
• 2가
• 3가
• 기타
• 세계의 유행성 이하선염 백신(MumpsVax) 시장 : 연령층별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 소아
• 성인
• 세계의 유행성 이하선염 백신(MumpsVax) 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 약국
• 소매 약국
• 세계의 유행성 이하선염 백신(MumpsVax) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 소아과 클리닉
• 병원
• 비정부기구(NGO)
• 기타

제9장 임상적응증 세계 시장 역학

• 약제의 부작용
• 임상적응증의 발병률과 유병률

제10장 지역별, 국가별 분석

• 세계의 유행성 이하선염 백신(MumpsVax) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 유행성 이하선염 백신(MumpsVax) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 경쟁 구도와 기업 프로파일

• 유행성 이하선염 백신(MumpsVax) 시장 : 경쟁 구도
• 유행성 이하선염 백신(MumpsVax) 시장 : 기업 프로파일
  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Sinovac BIoTech Ltd.
  • Serum Institute of India Pvt. Ltd.
  • Shaurya International

제29장 세계 시장 : 파이프라인 분석

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 최근 시장 동향

제33장 시장의 잠재력이 높은 국가, 전략

• 유행성 이하선염 백신(MumpsVax) 시장(2029년) : 새로운 기회를 제공하는 국가
• 유행성 이하선염 백신(MumpsVax) 시장(2029년) : 새로운 기회를 제공하는 부문
• 유행성 이하선염 백신(MumpsVax) 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제34장 부록

HBR

영문 목차

영문목차

The mumps vaccine (MumpsVax) is a live attenuated vaccine that protects against mumps by using the Jeryl Lynn strain of the virus. It is typically administered in two doses and is commonly combined with the MMR (measles, mumps, rubella) vaccine, offering more than 95% protection against mumps. Although standalone production of the mumps vaccine has been discontinued, it continues to play a vital role in public health initiatives to control mumps outbreaks, significantly reducing the incidence of the disease in vaccinated populations.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Mumps vaccine (MumpsVax) is available in several product types, including monovalent, combinational, divalent, trivalent, and others. Monovalent vaccines specifically target mumps, while combinational vaccines provide protection against multiple diseases, such as measles and rubella, in a single shot. The vaccine is used by both pediatric and adult age groups, with distribution through hospital pharmacies, drug stores, and retail pharmacies. It is utilized by a range of end-users, including pediatric clinics, hospitals, non-governmental organizations (NGOs), and others.

The mumps vaccine (mumpsvax) market research report is one of a series of new reports from The Business Research Company that provides mumps vaccine (mumpsvax) market statistics, including mumps vaccine (mumpsvax) industry global market size, regional shares, competitors with a mumps vaccine (mumpsvax) market share, detailed mumps vaccine (mumpsvax) market segments, market trends and opportunities, and any further data you may need to thrive in the mumps vaccine (mumpsvax) industry. This mumps vaccine (mumpsvax) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mumps vaccine (mumpsvax) market size is expected to see strong growth in the next few years. It will grow to $2,902.2 million in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to the rising incidence of vaccine-preventable diseases, growing adult vaccination awareness, rising health consciousness, increasing immunization programs, and increasing international health initiatives. Major trends in the forecast period include personalized vaccination strategies, digital health integration, enhanced surveillance systems, R&D for adult vaccination, and integration of artificial intelligence.

The rising prevalence of infectious diseases is expected to propel the growth of the mumps vaccine (mumpsvax) market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms, such as viruses, bacteria, fungi, or parasites, which can be transmitted between individuals or through contaminated environments. Factors such as urbanization, climate change, globalization, and changes in human demographics and behavior contribute to the increased transmission and emergence of pathogens. Mumpsvax is primarily used to prevent mumps, an infectious disease caused by the mumps virus, often included in the MMR (measles, mumps, rubella) vaccination. For instance, in August 2024, the UK Health Security Agency reported a rise in measles cases, with the West Midlands region having the highest number of cases in 2023, contributing to a rise in mumps vaccinations as part of the broader infectious disease prevention efforts. Therefore, the rise in infectious diseases drives the mumps vaccine (mumpsvax) market.

Rising healthcare expenditure is expected to propel the growth of the mumps vaccine (mumpsvax) market. Healthcare expenditure refers to the total amount spent on health care goods and services, including personal healthcare, preventive services, and public health initiatives aimed at improving health outcomes. Factors like an aging population, chronic diseases, advanced medical technology, and increasing demand for services contribute to the rise in healthcare spending. This increase directly impacts Mumpsvax by improving funding for vaccination programs, thereby boosting vaccine accessibility and leading to higher immunization rates. For instance, in May 2024, the UK Office for National Statistics reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, reinforcing funding for vaccinations and improving public health outcomes. Therefore, the rise in healthcare expenditure drives the mumps vaccine (mumpsvax) market.

The increasing number of clinical trials is expected to propel the growth of the mumps vaccine (mumpsvax) market. Clinical trials are essential in advancing the understanding and treatment of various health conditions, including infectious diseases like mumps. Mumpsvax serves as a reliable tool for evaluating vaccine efficacy, safety, and immune response, particularly in trials focused on pediatric immunization and viral infections. For instance, in May 2023, Xtalks reported that over 452,000 clinical trials were registered globally, a significant increase from previous years. This growing number of clinical trials contributes to the continued development and assessment of vaccines like Mumpsvax. Therefore, the increase in clinical trials drives the mumps vaccine (mumpsvax) market.

Major players operating in the mumps vaccine (mumpsvax) market are Merck & Co. Inc.; GlaxoSmithKline plc

North America was the largest region in the mumps vaccine (mumpsvax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mumps vaccine (mumpsvax) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the mumps vaccine (mumpsvax) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mumps vaccine (mumpsvax) market consists of sales of mumps vaccines, including both standalone mumps vaccines and combination vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mumps Vaccine (MumpsVax) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mumps vaccine (mumpsvax) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mumps vaccine (mumpsvax) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mumps vaccine (mumpsvax) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Monovalent; Combinational; Divalent; Trivalent; Other Product Types
• 2) By Age Group: Pediatric; Adult
• 3) By Distribution Channels: Hospital pharmacies; Drug Stores; Retail Pharmacies
• 4) By End-User: Pediatric Clinic; Hospitals; Non-Governmental Organization (NGOs); Other End-Users
• Companies Mentioned: Merck & Co. Inc.; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Mumps Vaccine (MumpsVax) Market Characteristics

3. Mumps Vaccine (MumpsVax) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Mumps Vaccine (MumpsVax) Market Trends And Strategies

5. Mumps Vaccine (MumpsVax) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Mumps Vaccine (MumpsVax) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Mumps Vaccine (MumpsVax) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Mumps Vaccine (MumpsVax) Market Growth Rate Analysis
• 6.4. Global Mumps Vaccine (MumpsVax) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Mumps Vaccine (MumpsVax) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Mumps Vaccine (MumpsVax) Total Addressable Market (TAM)

7. Global Mumps Vaccine (MumpsVax) Market Pricing Analysis & Forecasts

8. Mumps Vaccine (MumpsVax) Market Segmentation

• 8.1. Global Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monovalent
• Combinational
• Divalent
• Trivalent
• Other Product Types
• 8.2. Global Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult
• 8.3. Global Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals Pharmacies
• Drug Stores
• Retail Pharmacies
• 8.4. Global Mumps Vaccine (MumpsVax) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Clinic
• Hospitals
• Non-Governmental Organization (NGOs)
• Other End-Users

9. Global Mumps Vaccine (MumpsVax) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Mumps Vaccine (MumpsVax) Market Regional And Country Analysis

• 10.1. Global Mumps Vaccine (MumpsVax) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Mumps Vaccine (MumpsVax) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Mumps Vaccine (MumpsVax) Market

• 11.1. Asia-Pacific Mumps Vaccine (MumpsVax) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Mumps Vaccine (MumpsVax) Market

• 12.1. China Mumps Vaccine (MumpsVax) Market Overview
• 12.2. China Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Mumps Vaccine (MumpsVax) Market

• 13.1. India Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Mumps Vaccine (MumpsVax) Market

• 14.1. Japan Mumps Vaccine (MumpsVax) Market Overview
• 14.2. Japan Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Mumps Vaccine (MumpsVax) Market

• 15.1. Australia Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Mumps Vaccine (MumpsVax) Market

• 16.1. South Korea Mumps Vaccine (MumpsVax) Market Overview
• 16.2. South Korea Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Mumps Vaccine (MumpsVax) Market

• 17.1. Western Europe Mumps Vaccine (MumpsVax) Market Overview
• 17.2. Western Europe Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Mumps Vaccine (MumpsVax) Market

• 18.1. UK Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Mumps Vaccine (MumpsVax) Market

• 19.1. Germany Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Mumps Vaccine (MumpsVax) Market

• 20.1. France Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Mumps Vaccine (MumpsVax) Market

• 21.1. Eastern Europe Mumps Vaccine (MumpsVax) Market Overview
• 21.2. Eastern Europe Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Mumps Vaccine (MumpsVax) Market

• 22.1. North America Mumps Vaccine (MumpsVax) Market Overview
• 22.2. North America Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Mumps Vaccine (MumpsVax) Market

• 23.1. USA Mumps Vaccine (MumpsVax) Market Overview
• 23.2. USA Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Mumps Vaccine (MumpsVax) Market

• 24.1. Canada Mumps Vaccine (MumpsVax) Market Overview
• 24.2. Canada Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Mumps Vaccine (MumpsVax) Market

• 25.1. South America Mumps Vaccine (MumpsVax) Market Overview
• 25.2. South America Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Mumps Vaccine (MumpsVax) Market

• 26.1. Middle East Mumps Vaccine (MumpsVax) Market Overview
• 26.2. Middle East Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Mumps Vaccine (MumpsVax) Market

• 27.1. Africa Mumps Vaccine (MumpsVax) Market Overview
• 27.2. Africa Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Mumps Vaccine (MumpsVax) Market Competitive Landscape And Company Profiles

• 28.1. Mumps Vaccine (MumpsVax) Market Competitive Landscape
• 28.2. Mumps Vaccine (MumpsVax) Market Company Profiles
  • 28.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.3. Sinovac Biotech Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.4. Serum Institute of India Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.5. Shaurya International Overview, Products and Services, Strategy and Financial Analysis

29. Global Mumps Vaccine (MumpsVax) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Mumps Vaccine (MumpsVax) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Mumps Vaccine (MumpsVax) Market

32. Recent Developments In The Mumps Vaccine (MumpsVax) Market

33. Mumps Vaccine (MumpsVax) Market High Potential Countries, Segments and Strategies

• 33.1 Mumps Vaccine (MumpsVax) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Mumps Vaccine (MumpsVax) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Mumps Vaccine (MumpsVax) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer

관련자료